Skip to content

Verena Angerer

b Department of Forensic Toxicology, Institute of Forensic Medicine , Medical Center - University of Freiburg , Germany.

2 papers in the library · 28 citations · publishing 2017-2024

Papers

Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus.

Clinical toxicology (Philadelphia, Pa.) September 1, 2017 Maren Hermanns-Clausen, Verena Angerer, Josephine Kithinji et al. 22 citations

A 42-year-old man accidentally ingested 25I-NBOMe, a potent hallucinogenic drug, after taking a sip of pediatric analgesic syrup that had been refilled with a self-made solution of the drug in ethanol. Within 30 minutes he became restless, and in the emergency department he showed dilated pupils, heavy sweating, disorientation, agitation, and later severe agitation, coenesthesia, and complex hallucinations. Blood tests at admission detected 25I-NBOMe (34 ng/mL), its metabolite 2C-I (12 ng/mL), and 25I-NBOH (<1 ng/mL). The syrup contained 2800 μg/mL of 25I-NBOMe. Symptoms resolved after six hours without complications. The presence of 2C-I 50 minutes after intake suggests rapid metabolic breakdown of 25I-NBOMe via first-pass metabolism.

Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.

Drug testing and analysis September 1, 2024 Verena Angerer, Yasmin Schmid, Florian Franz et al. 6 citations

In six healthy volunteers, the new psychoactive substance MDAI at 3.0 mg/kg produced subjective effects comparable to 125 mg of MDMA, including increased blood pressure, but did not raise heart rate or body temperature. MDAI increased cortisol and prolactin levels, appeared in serum about 20 minutes after ingestion, and remained detectable for at least 4 days in serum and 6 days in urine. The drug was well tolerated. Further research is needed to evaluate whether MDAI might have medicinal applications.